Autolus Competitors
| AUTL Stock | USD 1.37 0.06 4.20% |
Autolus Therapeutics vs Aura Biosciences Correlation
Good diversification
The correlation between Autolus Therapeutics and AURA is -0.01 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Autolus Therapeutics and AURA in the same portfolio, assuming nothing else is changed.
Moving against Autolus Stock
The value of Return On Tangible Assets is estimated to slide to -0.27. The value of Return On Capital Employed is expected to slide to -0.4. At this time, Autolus Therapeutics' Debt To Assets are quite stable compared to the past year. Fixed Asset Turnover is expected to rise to 0.13 this year, although the value of Other Current Assets will most likely fall to about 13 M.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Autolus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Autolus Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Autolus Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Autolus and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Autolus Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Autolus Stock performing well and Autolus Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Autolus Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SLDB | 3.67 | 0.19 | 0.05 | 0.14 | 4.40 | 11.36 | 21.63 | |||
| QSI | 3.42 | (1.12) | 0.00 | (0.34) | 0.00 | 6.50 | 15.95 | |||
| RCKT | 2.92 | (0.18) | 0.00 | (0.09) | 0.00 | 8.04 | 16.20 | |||
| LBRX | 3.76 | 0.52 | 0.11 | (0.64) | 3.67 | 9.38 | 23.59 | |||
| ADCT | 3.26 | (0.20) | 0.00 | (0.18) | 0.00 | 8.49 | 22.84 | |||
| NMRA | 3.89 | (0.34) | 0.00 | (0.38) | 0.00 | 9.77 | 33.25 | |||
| RAPT | 3.93 | 1.37 | 0.32 | (0.44) | 3.04 | 7.87 | 64.05 | |||
| BNTC | 3.11 | (0.32) | 0.00 | (0.20) | 0.00 | 5.86 | 26.95 | |||
| ANNX | 4.24 | 1.00 | 0.24 | 6.88 | 3.42 | 11.30 | 35.10 | |||
| AURA | 2.38 | (0.14) | 0.00 | (0.05) | 0.00 | 4.74 | 18.08 |
Cross Equities Net Income Analysis
Compare Autolus Therapeutics and related stocks such as Solid Biosciences LLC, QuantumSi, and Rocket Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SLDB | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (21.5 M) | (52.1 M) | (74.8 M) | (117.2 M) | (88.3 M) | (72.2 M) | (86 M) | (96 M) | (124.7 M) | (112.2 M) | (117.8 M) |
| QSI | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (36.6 M) | (95 M) | (132.4 M) | (96 M) | (101 M) | (90.9 M) | (95.5 M) |
| RCKT | (6.1 M) | (6.1 M) | (6.1 M) | (7.6 M) | (9.5 M) | (68 M) | (42.9 M) | (29.5 M) | (74.5 M) | (83.2 M) | (146.7 M) | (169.1 M) | (221.9 M) | (245.6 M) | (258.7 M) | (232.9 M) | (221.2 M) |
| LBRX | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (6.3 M) | (63.1 M) | (56.8 M) | (54 M) |
| ADCT | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (123.1 M) | (116.5 M) | (246.3 M) | (230 M) | (157.1 M) | (240.1 M) | (157.8 M) | (142.1 M) | (149.2 M) |
| NMRA | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (237.3 M) | (130.9 M) | (235.9 M) | (243.8 M) | (219.4 M) | (230.4 M) |
| RAPT | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (36.1 M) | (43 M) | (52.9 M) | (68.2 M) | (81.9 M) | (116.8 M) | (129.9 M) | (116.9 M) | (111 M) |
| BNTC | (6.4 M) | (6.4 M) | (6.4 M) | (10.8 M) | (8.8 M) | (18.5 M) | (4.4 M) | (8.6 M) | 2.9 M | (8.3 M) | (13.9 M) | (18.2 M) | (19.6 M) | (21.8 M) | (37.9 M) | (34.1 M) | (32.4 M) |
| ANNX | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.3 M) | (37.2 M) | (62.7 M) | (127.8 M) | (138.3 M) | (134.2 M) | (138.2 M) | (124.4 M) | (130.6 M) |
| AURA | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (22.2 M) | (35.3 M) | (58.8 M) | (76.4 M) | (86.9 M) | (78.2 M) | (82.1 M) |
Autolus Therapeutics and related stocks such as Solid Biosciences LLC, QuantumSi, and Rocket Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Autolus Therapeutics financial statement analysis. It represents the amount of money remaining after all of Autolus Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Autolus Therapeutics Competitive Analysis
The better you understand Autolus Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Autolus Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Autolus Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Autolus Therapeutics Competition Performance Charts
Five steps to successful analysis of Autolus Therapeutics Competition
Autolus Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Autolus Therapeutics in relation to its competition. Autolus Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Autolus Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Autolus Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Autolus Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Autolus Therapeutics position
In addition to having Autolus Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Agency Mbs ETFs Thematic Idea Now
Agency Mbs ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Agency Mbs ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Agency Mbs ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Autolus Therapeutics Correlation with its peers. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Autolus Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.80) | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Autolus Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Autolus Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Autolus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.